XRF Scientific Boosts Portfolio with Acquisition of Bruker's CGA Business

XRF Scientific (ASX: XRF) is acquiring Bruker AXS SE’s Combustion Gas Analysis (CGA) business for USD 4.0 million upfront, expanding its product portfolio and bringing manufacturing to Australia.

The acquisition's upfront consideration is USD 4.0 million, which will be funded from XRF's existing cash reserves.

An additional earnout of up to USD 1.0 million is payable over three years, based on 7% of net CGA revenue.

Completion of the acquisition—which includes a suite of **CS/OHN elemental analysers—**is expected this week.

There are no conditions precedent, simplifying the closing process.

Strategic Rationale and Revenue Outlook

The acquisition is set to significantly expand XRF's product portfolio, moving into non-mining industrial sectors—a key diversification benefit cited by the company.

Crucially, key sales management and technical support employees from Bruker in Germany and the USA will join XRF.

This transition of personnel helps maintain customer relationships and product expertise.

Revenue generation from the acquired business is not expected until Q4 2026, following a planned manufacturing transition.

The company also sees opportunities to add consumable revenue streams and cross-sell with existing XRF instruments.

Manufacturing Transition and Execution Risks

Manufacturing operations for the CGA products will transition from Karlsruhe, Germany, to XRF’s factory in Perth, Australia.

This significant operational shift is expected to conclude during Q3 2026.

The company has explicitly noted that this manufacturing transfer may introduce execution and ramp-up risks.

This type of transition requires careful management to ensure smooth operations and maintain product quality.

Financial Context and Performance

The upfront acquisition cost of USD 4.0 million implies an initial multiple of approximately 0.75x CGA's 2025 unaudited revenue of USD 5.3 million.

XRF Scientific has demonstrated robust financial health, reporting revenue of AUD 15.8 million in its March 2026 quarter, a 13.8% increase year on year.

Profit before tax for the quarter was AUD 3.7 million, up 10.7%.

The company maintains a healthy net cash position and positive operating cash flow from its existing operations, providing a stable foundation for this acquisition.

Investment Considerations

XRF Scientific's acquisition of Bruker's CGA business represents a strategic expansion into new industrial markets.

While the deal adds a potentially profitable product line, investors will monitor the execution of the manufacturing transition and the timeline for revenue generation.

The company's existing financial strength and positive trading performance provide a stable foundation, but risks related to integration and operational ramp-up warrant caution.